 The FDA has signed off Phase 12 clinical study to evaluate XBiotech Incs NASDAQ: XBIT XB2001 when added to the ONIVYDE5-FU combination therapy for treating patients with pancreatic cancer. The Phase 1 portion of the study will examine increasing doses of XBiotechs new drug and assess the tolerability of the combination at escalating doses. 